clinical trial · NCT06960577
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca·phase3·recruiting·n = 150
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexateVinblastineDoxorubicinCisplatinGemcitabineDurvalumabMethotrexateVinblastineDoxorubicinCisplatinDurvalumabGemcitabineCisplatin
brief summary
The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.
started
May 15, 2025
primary completion
Oct 31, 2028
completion
Oct 31, 2028
last updated
Apr 23, 2026
detailed description
Not provided
official title
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol